NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024
NHS England · awarded 28 October 2024
£626.5m
Award value
£626,522,476
13
Suppliers
Size not recorded
31 Oct 2026
Runs until
from 1 Nov 2024
Who
| Buyer | NHS England Runcorn |
|---|---|
| Suppliers |
Abbvie Ltd Amarox Limited Dr.Reddy's Laboratories (UK) Limited Gilead Sciences Limited Janssen-Cilag Ltd Lupin Healthcare (UK) Limited MSN Laboratories Europe Limited Macleods Pharma UK Limited Mawdsley-Brooks & Co Ltd Merck Sharpe & Dohme (UK) Limited Milpharm Ltd/aurobinbdo Primary Mylan ViiV Healthcare UK Ltd |
| Category | goods |
| Classification | Pharmaceutical products CPV 33600000 |
| Notice published | 28 November 2024 |
What it is for
Project title: NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) for the treatment of HIV (Lot 1) & For the provision of a service to supply over labelled Pre-Exposure Prophylaxis (PrEP) and Post-Exposure Prophylaxis (PEP) Packs for the prevention of HIV (Lot 2) 1st November 2024 Offer reference number: CM/PHS/24/5709 Period of framework agreement: 1st November 2024 to 31st October 2026 with an option to extend (at the Authority's discretion) for a further period (or periods) up to a total of 24 months.
Read the original award notice on Contracts Finder →
Other contracts from this buyer
1269 awards on file, worth £50.2bn.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 4 Mar 2026 | New Hospital Programme - Hospital 2.0 Alliance (H2A) FrameworkEngland | NHS England | Willmott Dixon Construction Limited +9 | £37.0bn |
| 24 Mar 2025 | NHS Framework Agreement for Branded Medicines - Proprietary Category TenderEast Midlands | NHS England | CSL Behring UK Ltd +71 | £1.2bn |
| 1 Jul 2025 | NHS Branded Medicines Tranche B - MAE & NOFE - 1 September 2025 | NHS England | Biogen +20 | £986.3m |
| 19 Dec 2024 | NHS Framework Agreement for Human Albumin & Normal and Anti-D ImmunoglobulinScotland | NHS England | CSL Behring UK Ltd +5 | £905.2m |
| 31 May 2024 | NHS Framework - Blood Disorders including Haemophilia A and B - July 2024East Midlands | NHS England | Pfizer Ltd +8 | £765.0m |
Everything NHS England has awarded →
Other contracts won by this supplier
2 awards on file, worth £642.7m.
| Awarded | What for | Buyer | Supplier | Value |
|---|---|---|---|---|
| 28 Oct 2024 | NHS Framework for the supply of Licensed Antiretroviral Therapy (ART) 1 Nov 2024 | NHS England | Gilead Sciences Limited +12 | £626.5m |
| 30 Sep 2024 | NHS National Framework for Transition products commencing 1 October 2024East Midlands | NHS England | Thornton and Ross Ltd +11 | £16.2m |